A
Andrew Z. Wang
Researcher at University of North Carolina at Chapel Hill
Publications - 194
Citations - 13074
Andrew Z. Wang is an academic researcher from University of North Carolina at Chapel Hill. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 46, co-authored 171 publications receiving 10927 citations. Previous affiliations of Andrew Z. Wang include Massachusetts Institute of Technology & Dresden University of Technology.
Papers
More filters
Journal ArticleDOI
Nanoparticles in Medicine: Therapeutic Applications and Developments
TL;DR: Nanomaterials have unique physicochemical properties, such as ultra small size, large surface area to mass ratio, and high reactivity, which are different from bulk materials of the same composition, which can be used to overcome some of the limitations found in traditional therapeutic and diagnostic agents.
Journal ArticleDOI
Self-assembled lipid--polymer hybrid nanoparticles: a robust drug delivery platform.
Liangfang Zhang,Juliana M. Chan,Frank X. Gu,June-Wha Rhee,Andrew Z. Wang,Andrew Z. Wang,Aleksandar Filip Radovic-Moreno,Frank Alexis,Frank Alexis,Robert Langer,Omid C. Farokhzad +10 more
TL;DR: The engineering of a novel lipid-polymer hybrid nanoparticle (NP) as a robust drug delivery platform, with high drug encapsulation yield, tunable and sustained drug release profile, excellent serum stability, and potential for differential targeting of cells or tissues is reported.
Journal ArticleDOI
Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers.
Frank X. Gu,Liangfang Zhang,Benjamin A. Teply,Nina Mann,Andrew Z. Wang,Andrew Z. Wang,Aleksandar Filip Radovic-Moreno,Robert Langer,Omid C. Farokhzad,Omid C. Farokhzad +9 more
TL;DR: This work developed a series of targeted NPs with increasing Apt densities that inversely affected the amount of PEG exposure on NP surface and identified the narrow range of Apt density when the NPs were maximally targeted and maximally stealth, resulting in most efficient PCa cell uptake in vitro and in vivo.
Journal ArticleDOI
Clinical Translation of Nanomedicine.
TL;DR: The typical clinical translation path for a new drug starts with investigators generating robust preclinical data to demonstrate the safety and efficacy of the new drug to enable an investigational new drug (IND) application with the Food and Drug Administration (FDA).
Journal ArticleDOI
Using mechanobiological mimicry of red blood cells to extend circulation times of hydrogel microparticles
Timothy J. Merkel,Stephen W. Jones,Kevin P. Herlihy,Farrell R. Kersey,A. R. Shields,Mary E. Napier,J. Christopher Luft,Huali Wu,William C. Zamboni,Andrew Z. Wang,James E. Bear,Joseph M. DeSimone +11 more
TL;DR: Lowering the modulus of hydrogel microparticles altered their biodistribution properties, allowing them to bypass several organs, such as the lung, that entrapped their more rigid counterparts, resulting in increasingly longer circulation times well past those of conventionalmicroparticles.